Regent Pacific Group（RPG）株式概要リージェント・パシフィック・グループ・リミテッドは投資持株会社で、欧州、米国、アジア太平洋地域のヘルスケアおよびライフサイエンス部門に投資している。 詳細RPG ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6リスク分析マイナスの株主資本 収益が 100 万ドル未満 ( $363K )過去1年間で株主の希薄化が進んだ 意味のある時価総額がありません ( €21M )すべてのリスクチェックを見るRPG Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€0.06986.2k% 割高 内在価値ディスカウントEst. Revenue$PastFuture-66m6m2016201920222025202620282031Revenue US$10.8kEarnings US$1.6kAdvancedSet Fair ValueView all narrativesRegent Pacific Group Limited 競合他社Cantourage GroupSymbol: XTRA:HIGHMarket cap: €75.3mBiofronteraSymbol: XTRA:B8FKMarket cap: €14.6mTFF PharmaceuticalsSymbol: MUN:0K30Market cap: €9.7mMPH Health CareSymbol: DB:93M1Market cap: €110.0m価格と性能株価の高値、安値、推移の概要Regent Pacific Group過去の株価現在の株価HK$0.06952週高値HK$0.1252週安値HK$0.055ベータ1.191ヶ月の変化9.52%3ヶ月変化-31.68%1年変化-31.00%3年間の変化130.00%5年間の変化-75.36%IPOからの変化-91.38%最新ニュースBoard Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Adrian Alan Chan was the last director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • May 07Regent Pacific Group Limited, Annual General Meeting, May 29, 2026Regent Pacific Group Limited, Annual General Meeting, May 29, 2026, at 15:00 China Standard Time. Location: room 302, 3/f, first commercial building, 33-35 leighton road, causeway bay, Hong Kongお知らせ • Mar 16Regent Pacific Group Limited to Report Fiscal Year 2025 Results on Mar 26, 2026Regent Pacific Group Limited announced that they will report fiscal year 2025 results at 12:30 PM, China Standard Time on Mar 26, 2026お知らせ • Aug 15Regent Pacific Group Limited to Report First Half, 2025 Results on Aug 27, 2025Regent Pacific Group Limited announced that they will report first half, 2025 results on Aug 27, 2025お知らせ • Jun 30Regent Pacific Group Limited Announces Change in Composition of the Nomination CommitteeRegent Pacific Group Limited announced that Mrs. Jayne Sutcliffe, a Non-Executive Director, and Mr. Ihsan Al Chalabi, an Independent Non-Executive Director, have been appointed as a member of the nomination committee of the Company (the "Nomination Committee") with effect from 30 June 2025. Following the above changes, the composition of the Nomination Committee comprises five members, namely James Mellon (Chairman of the Nomination Committee), Jayne Sutcliffe, Mark Searle, Adrian Chan and Ihsan Al Chalabi.お知らせ • Apr 28Regent Pacific Group Limited, Annual General Meeting, Jun 19, 2025Regent Pacific Group Limited, Annual General Meeting, Jun 19, 2025, at 15:00 China Standard Time. Location: 14/f, fairmont house, 8 cotton tree drive, central, Hong Kong最新情報をもっと見るRecent updatesBoard Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Adrian Alan Chan was the last director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • May 07Regent Pacific Group Limited, Annual General Meeting, May 29, 2026Regent Pacific Group Limited, Annual General Meeting, May 29, 2026, at 15:00 China Standard Time. Location: room 302, 3/f, first commercial building, 33-35 leighton road, causeway bay, Hong Kongお知らせ • Mar 16Regent Pacific Group Limited to Report Fiscal Year 2025 Results on Mar 26, 2026Regent Pacific Group Limited announced that they will report fiscal year 2025 results at 12:30 PM, China Standard Time on Mar 26, 2026お知らせ • Aug 15Regent Pacific Group Limited to Report First Half, 2025 Results on Aug 27, 2025Regent Pacific Group Limited announced that they will report first half, 2025 results on Aug 27, 2025お知らせ • Jun 30Regent Pacific Group Limited Announces Change in Composition of the Nomination CommitteeRegent Pacific Group Limited announced that Mrs. Jayne Sutcliffe, a Non-Executive Director, and Mr. Ihsan Al Chalabi, an Independent Non-Executive Director, have been appointed as a member of the nomination committee of the Company (the "Nomination Committee") with effect from 30 June 2025. Following the above changes, the composition of the Nomination Committee comprises five members, namely James Mellon (Chairman of the Nomination Committee), Jayne Sutcliffe, Mark Searle, Adrian Chan and Ihsan Al Chalabi.お知らせ • Apr 28Regent Pacific Group Limited, Annual General Meeting, Jun 19, 2025Regent Pacific Group Limited, Annual General Meeting, Jun 19, 2025, at 15:00 China Standard Time. Location: 14/f, fairmont house, 8 cotton tree drive, central, Hong Kongお知らせ • Mar 17Regent Pacific Group Limited to Report Fiscal Year 2024 Results on Mar 27, 2025Regent Pacific Group Limited announced that they will report fiscal year 2024 results on Mar 27, 2025お知らせ • Dec 19Regent Pacific Group Limited Announces Submission of Senstend New Drug Application to the National Medical Products Administration in ChinaThe Board announced that commercial strategic partner Jiang Su Wan Bang Sheng Hua Yi Yao Ji Tuan You Xian Ze Ren Gong Si (Jiangsu Wanbang Biopharmaceutical Group Co. Ltd.) ("Wanbang Biopharmaceutical", a wholly-controlled company of Shanghai Fosun Pharmaceutical (Group) Co. Ltd. ("Fosun")) has submitted the New Drug Application ("NDA") registration dossier with the National Medical Products Administration ("NMPA") on 17 December 2024, with approval expected within 12 months from the submission date. Wanbang Biopharmaceutical is responsible, at its own expense, for obtaining the NDA from NMPA and maintaining any and all regulatory approvals required for the importation of Senstend in the People's Republic of China ("China" or "PRC"). In addition, and importantly, Wanbang Biopharmaceutical has signed an exclusive manufacturing and supply agreement with, inter alia, Genetic S.p. A. ("Genetic") and Jiang Su Wan Bang Yi Yao Ying Xiao You Xian Gong Si (Wanbang Pharmaceutical Marketing and Distribution Co. Ltd) ("Wanbang MKT", an affiliate of Wanbang Biopharmaceutical) on 26 August 2024, where Genetic will manufacture and supply Senstend to Wanbang Biopharmaceutical based on purchase orders received from Wanbang Biopharmaceutical. As previously mentioned, on the NDA being approved by NMPA, USD 5 million (or approximately HKD 39 million) and on first commercial launch USD 2 million (or approximately HKD 15.60 million) will be payable to the Group from Wanbang Biopharm pharmaceutical.Reported Earnings • Sep 27First half 2024 earnings released: US$0.011 loss per share (vs US$0.055 loss in 1H 2023)First half 2024 results: US$0.011 loss per share (improved from US$0.055 loss in 1H 2023). Revenue: US$43.0k (down 85% from 1H 2023). Net loss: US$2.62m (loss narrowed 79% from 1H 2023). Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 51% per year, which means it is performing significantly worse than earnings.お知らせ • Aug 16Regent Pacific Group Limited to Report First Half, 2024 Results on Aug 28, 2024Regent Pacific Group Limited announced that they will report first half, 2024 results on Aug 28, 2024お知らせ • Apr 28Regent Pacific Group Limited, Annual General Meeting, May 30, 2024Regent Pacific Group Limited, Annual General Meeting, May 30, 2024, at 15:00 China Standard Time. Location: 14/F, Fairmont House, 8 Cotton Tree Drive, Central Hong Kong Agenda: To receive, consider and adopt the audited financial statements of the Company and the reports of the Directors and the independent auditor of the Company for the year ended 31 December 2023; to re-appoint RSM Hong Kong as the independent auditor of the Company and to authorise the Board to fix their remuneration; to re-elect the following Directors, each as a separate ordinary resolution, and to authorise the Board to fix the remuneration of the Directors for the year ending 31 December 2024; and to consider other matters.Reported Earnings • Mar 29Full year 2023 earnings released: US$0.11 loss per share (vs US$0.30 loss in FY 2022)Full year 2023 results: US$0.11 loss per share (improved from US$0.30 loss in FY 2022). Net loss: US$25.0m (loss narrowed 31% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has fallen by 51% per year, which means it is performing significantly worse than earnings.お知らせ • Mar 26Qujing Black Gold Energy Co., Ltd. entered into a sale and purchase agreement to acquire 25% stake in West China Coking & Gas Company Limited from Regent Pacific Group Limited (SEHK:575) for CNY 8 million.Qujing Black Gold Energy Co., Ltd. entered into a sale and purchase agreement to acquire 25% stake in West China Coking & Gas Company Limited from Regent Pacific Group Limited (SEHK:575) for CNY 8 million on March 24, 2024. The consideration consists of CNY 8 million in cash. As part of the consideration, CNY 8 million was paid towards common equity. . West China Coking & Gas Company Limited reported the unaudited net loss of CNY 8.9 million as at 31 December 2023. The completion of the transaction is conditional upon all necessary corporate, governmental or regulatory approvals of the Disposal (the “Conditions”) including but not limited to unanimous approval from the shareholders of the Target Company and any relevant PRC governmental or regulatory bodies.お知らせ • Mar 16Regent Pacific Group Limited to Report Fiscal Year 2023 Results on Mar 27, 2024Regent Pacific Group Limited announced that they will report fiscal year 2023 results on Mar 27, 2024お知らせ • Aug 18Regent Pacific Group Limited to Report First Half, 2023 Results on Aug 29, 2023Regent Pacific Group Limited announced that they will report first half, 2023 results on Aug 29, 2023お知らせ • Jul 23Regent Pacific Group Limited Provides Consolidated Earnings Guidance for the Period Ended 30 June 2023Regent Pacific Group Limited provided consolidated earnings guidance for the period ended 30 June 2023. The group expects to record a loss attributable to the equity holders of the company for the period ended 30 June 2023 (the "Reporting Period") of between approximately USD 12 million (or approximately HKD 93.60 million) to approximately USD 15 million (or approximately HKD 117 million), which represents a substantial decrease in the loss as compared to a loss attributable to the equity holders of the Company of approximately USD 20.06 million (or approximately HKD 156.47 million) for the period ended 30 June 2022 (the "Corresponding Period").Board Change • Jul 12Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 5 highly experienced directors. Independent Non-Executive Director Julie Oates was the last director to join the board, commencing their role in 2004. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Reported Earnings • Mar 30Full year 2022 earnings released: US$0.015 loss per share (vs US$0.005 loss in FY 2021)Full year 2022 results: US$0.015 loss per share (further deteriorated from US$0.005 loss in FY 2021). Net loss: US$36.4m (loss widened 189% from FY 2021). Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has only increased by 39% per year, which means it is significantly lagging earnings growth.お知らせ • Feb 18Endurance RP Limited Provides Earnings Guidance for the Year Ended 31 December 2022Endurance RP Limited provided earnings guidance for the year ended 31 December 2022. For the year, the Group expects to record a loss attributable to the equity holders of the Company of between approximately USD 33 million (or approximately HKD 257.40 million) to approximately USD 36 million (or approximately HKD 280.80 million), which represents a substantial increase in the loss as compared to the loss attributable to the equity holders of the Company of approximately USD12.60 million (or approximately HKD 98.28 million) for the year ended 31 December 2021 (the Corresponding Period).Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 5 highly experienced directors. Independent Non-Executive Director Charles David Comba was the last director to join the board, commencing their role in 2005. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • Aug 19Endurance RP Limited to Report First Half, 2022 Results on Aug 30, 2022Endurance RP Limited announced that they will report first half, 2022 results on Aug 30, 2022お知らせ • Jul 23Endurance RP Limited Provides Unaudited Consolidated Earnings Guidance for the Period Ended 30 June 2022Endurance RP Limited provided unaudited consolidated earnings guidance for the period ended 30 June 2022. For the period, the Group expects to record a loss attributable to the equity holders of the Company between approximately USD 20 million (or approximately HKD 156 million) to approximately USD 23 million (or approximately HKD 179.40 million), which represents a loss as compared to a profit attributable to the equity holders of the Company of approximately USD 2.66 million (or approximately HKD 20.75 million) for the period ended 30 June 2021.お知らせ • Jul 06Endurance Rp Limited Announces Operational Update on the PE Prevention Drug Fortacin/ SenstendEndurance RP Limited provided updates on the PE prevention drug - Fortacin /Senstend (the marketing name of Fortacin in China). Regarding the clinical study for seeking approval of an import licence for Senstend™ from the National Medical Products Administration of The People's Republic of China ("China"), among the three drug trials that Wanbang Biopharmaceutical Co. Ltd. (Wanbang Biopharmaceutical), the Company's commercial strategic partner for China and a wholly controlled company of Shanghai Fosun Pharmaceutical (Group) Co. Ltd. registered in December 2021 with the Centre of Drug Evaluation, the two Phase 1 studies have been successfully completed and the remaining Phase 3 study remains ongoing. Despite certain COVID-19 lockdowns and restrictions being experienced in China, the Phase 3 study has commenced with 177 patients having signed informed consent forms to enter the study (approximately 62% complete) and 88 subjects having been randomised into the study (approximately 31% complete) as of 1 July 2022. Wanbang Biopharmaceutical has advised the Company that even with the aforementioned COVID-19 lockdowns and restrictions, enrolment and randomisation is estimated to complete in November 2022. The preparatory phase for preparing the New Drug Application ("NDA") to NMPA have been commenced with the aim of submitting the NDA by the end of Second Quarter 2023. All costs of the clinical trials, including all other associated regulatory and submission costs are being met by Wanbang Biopharmaceutical. If the clinical study meets its endpoints and the NMPA grants an import licence for Senstend, USD 5 million (or approximately HKD 39 million before deduction of PRC withholding tax) will be payable to the Group from Wanbang Biopharmaceutical. In addition, upon first commercial sale of Senstend in China, USD 2 million (or approximately HKD 15.60 million before deduction of PRC withholding tax) shall be payable to the Group from Wanbang Biopharmaceutical.Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 5 highly experienced directors. Independent Non-Executive Director Charles David Comba was the last director to join the board, commencing their role in 2005. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Reported Earnings • Mar 31Full year 2021 earnings releasedFull year 2021 results: Revenue: US$18.2m (up US$17.0m from FY 2020). Net loss: US$12.6m (loss narrowed 48% from FY 2020).お知らせ • Feb 16Endurance RP Limited Provides Consolidated Earnings Guidance for the Period Ended December 31, 2021Endurance RP Limited provided consolidated earnings guidance for the period ended December 31, 2021. For the year, the Group expects to record a loss attributable to the equity holders of the Company for the year ended31 December 2021 of between approximately USD 11.50 million (or approximately HKD 89.70 million) to approximately USD 14.00 million (or approximately HKD 109.20 million), which represents a substantial decrease in the loss as compared to a loss attributable to the equity holders of the Company of approximately USD 24.40 million (or approximately HKD 190.32 million) for the year ended 31 December 2020.Reported Earnings • Sep 28First half 2021 earnings released: EPS US$0.001 (vs US$0.015 loss in 1H 2020)First half 2021 results: Net income: US$2.66m (up US$29.8m from 1H 2020). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.お知らせ • Jul 16Endurance Rp Limited Announces Completion of Prespecified Data Analysis from the 16 Centre United States StudyEndurance RP Limited announced successful completion of prespecified data analysis from the 16 centre United States study undertaken to validate the Food and Drug Administration mandated patient reported outcome for premature ejaculation. The PRO, the Premature Ejaculation Bothersome Evaluation Questionnaire was developed compliant to FDA guidelines as the key final step for assessment of efficacy ahead of the Phase III randomised clinical trial already planned for the US. In this study, PSD502, marketed as FortacinTM in the European Union and the United Kingdom, produced substantial changes in intravaginal latency time ("IELT") and reduced the level of distress experienced by patients, as reflected in the PEBEQ. These results are entirely consistent with the previous extensive Phase III RCTs that were successfully completed prior to approval by the European Medicines Agency. The changes were clinically and statistically significant both from baseline and from placebo, resulting in an eight-to-nine-fold increase from pre-treatment IELT values. Also consistent with previous RCTs, compliance with therapy and with study requirements was high (over 92% completed in this study), and side effects were minimal. Clinically and statistically significant differences between Fortacin and placebo were observed in the FDA-favoured domain ("Item 3") of the PEBEQ (p< 0.0008). At the request of the FDA, Item 3 was designed to determine the degree of "bother" that the patients were experiencing due to the condition. For PRO validation, excellent correlations were also observed between changes in Item 3 of the PEBEQ and the domains of sexual satisfaction, control and distress captured using the Index of Premature Ejaculation ("IPE"), one of two PROs used in previous studies. The terms such as "bother" are important because they are used in the final approved prescribing information ("PI"). Overall, the study confirms the safety and efficacy of Fortacin. The new data will be used to refine the final Phase III RCT protocol, which is already prepared, and suitable clinical sites screen for expedient and good clinical practice enrolment. Formal registration of the Phase II validation study of FortacinTM is a critical and positive step towards making the new drug application ("NDA") submission and ultimately achieving all necessary FDA and other regulatory approvals needed to commercialise of FortacinTM in the US, its most significant potential market.Executive Departure • Jun 08Company Secretary Yuk Fung has left the companyOn the 1st of June, Yuk Fung's tenure as Company Secretary ended. We don't have any record of a personal shareholding under Yuk's name. Yuk is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 18.42 years.Reported Earnings • Apr 02Full year 2020 earnings released: US$0.013 loss per share (vs US$0.036 loss in FY 2019)Full year 2020 results: Net loss: US$24.4m (loss narrowed 63% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings.お知らせ • Mar 19Regent Pacific Group Limited to Report Fiscal Year 2020 Results on Mar 30, 2021Regent Pacific Group Limited announced that they will report fiscal year 2020 results on Mar 30, 2021お知らせ • Feb 10Wanbang Biopharmaceutical Group Co., Ltd. Obtains Clinical Trial Approval for Senstend from the Center of Drug Evaluation on February 5, 2021Regent Pacific Group Limited announced that Wanbang Biopharmaceutical Group Co. Ltd., the Company's commercial strategic partner for China, obtained Clinical Trial Approval for Senstend™ from the Center of Drug Evaluation on February 5, 2021, which has triggered a payment of $3.20 million before deduction of PRC withholding tax from Wanbang Biopharmaceutical. The randomised clinical trial is expected to commence in April/May 2021, with an estimated completion time of 12 months. Wanbang Biopharmaceutical has appointed a leading contract research organisation to undertake the randomised clinical trial. If the clinical study meets its endpoints and NMPA has granted an import licence for Senstend™, Regent Pacific will receive a payment of $5 million from Wanbang Biopharmaceutical. In addition, upon the first commercial sale of Senstend in China, the Group will receive another payment of $2 million from Wanbang Biopharmaceutical. In addition, the Group will generate low to mid-teens royalties of Wangbang Biopharmaceutical's net sales of Senstend in China.お知らせ • Jan 20Regent Pacific Group Limited Announces Operation Update on FortacinThe Directors of Regent Pacific Group Limited reported that Orient EuroPharma Co., Ltd. ("OEP"), the Group's commercial strategic partner for Taiwan, Hong Kong Special Administrative Region Macau Special Administrative Region ("Macau") and other select countries in Asia, has launched FortacinTM, the Group's prescription treatment for premature ejaculation, for sale in Hong Kong from this month. OEP has also informed the Group that it expects to launch FortacinTM in Macau in March 2021 and in Taiwan (its home market) in April 2021. The Group will generate a low teens royalty of OEP's net sales of FortacinTM in these markets. This marks a pivotal moment for the Group in realising its strategic goal of offering FortacinTM, through OEP, in its home market of Hong Kong. The Group also informed the shareholders that Wanbang Biopharmaceutical Group Co., Ltd., the Company's commercial strategic partner for China, has appointed a leading contract research organisation to undertake the randomised clinical trial in China. The randomised clinical trial is due to commence in April /May 2021, subject to the approval from National Medical Products Administration. The Group is in early discussions with a potential partner for "out licensing" the rights to FortacinTM for Japan. While these developments are indeed exciting, it is not possible to determine with accuracy the timing of completion of such discussions, and no assurance can be given that negotiations will lead to a binding Licensing agreement(s).お知らせ • Jan 05Regent Pacific Group Limited Announces Key Progresses on FORTACIN(TM)/SENSTEND(TM) - Solution to Premature EjaculationRegent Pacific Group Limited announced several key updates of Fortacin™/Senstend™, the first prescription solution to premature ejaculation (PE) that does not act on the central nervous system, in China and the United States respectively. Regent Pacific received USD 0.72 million (approximately HKD 5.62 million) from its commercial strategic partner in China -Wanbang Pharmaceutical Marketing and Distribution Co. Ltd. ("Wanbang Pharmaceutical"), a wholly controlled company of Shanghai Fosun Pharma to seek marketing approval of Senstend™ (the marketing name of Fortacin™ in China) in China on 29 December 2020. The Clinical Trial Approval ("CTA") of Senstend™ will be reviewed by the National Medical Products Administration ("NMPA") and is expected to be obtained from the Center of Drug Evaluation by the end of first quarter of 2021. Upon the successful approval from NMPA to commence the clinical trial, Regent Pacific will receive a payment of USD 3.20 million (approximately HKD 24.96 million) from Wanbang Pharmaceutical. Regent Pacific will receive USD 5 million (approximately HKD 39 million) from Wanbang Pharmaceutical if the clinical study tentatively to be started in April/May 2021 meets its endpoints of determining the effects of Senstend™ on the Index of Premature Ejaculation (IPE) and the Intra-vaginal Ejaculation Latency Time (IELT) and to evaluate the safety and tolerability of Senstend™ in Premature Ejaculation subjects and their sexual partners, together with an import licence for Senstend™ granted by NMPA. Regent Pacific will also receive USD 2 million (approximately HKD 15.6 million) upon the first commercial sale of Senstend™ in China from Wanbang Pharmaceutical with tiered percentage royalties on net sales, ranging from low to the high teens from first commercial sale.お知らせ • Dec 04Regent Pacific Group Limited Provides Operations Update on FortacinThe directors of Regent Pacific Group Limited provided update in respect of its operations in relation SenstendTM/FortacinTM. Further to the last operations update issued by the Company on 17 November 2020, the Directors are pleased to inform shareholders that Wanbang Pharmaceutical Marketing and Distribution Co. Ltd. ("Wanbang Pharmaceutical"), the Company's commercial strategic partner for China, has received approval from the National Medical Products Administration ("NMPA") to submit the investigational new drug application for human clinical trial of a Licensed Product at NMPA, which is an important milestone in achieving approval to market SenstendTM in China. Plethora has accordingly issued to Wanbang Pharmaceutical an invoice for USD 800,000 (or approximately HKD 6.24 million), which is payable within 30 business days. NMPA will now formally review for Clinical Trial Approval ("CTA") and the Company has been advised by Wanbang Pharmaceutical that the CTA will be obtained from the Center of Drug Evaluation within 60 working days (approximately 3 months) from the date of submission, i.e. by end of first quarter 2021. Upon the successful approval from NMPA to commence the clinical trial a payment of USD 3.20 million (or approximately HKD 24.96 million) will be due. The Group will continue to work closely and diligently with its current and prospective commercial partners and will keep shareholders and potential investors informed of any new developments as and when they occur.お知らせ • Nov 18Regent Pacific Announces Important Commercialisation Progress on Fortacin/ SenstendRegent Pacific Group Limited announced several important commercialisation progress on SENSTEND™ (the marketing name of FORTACIN™ in mainlandChina), the first prescription treatment for treating premature ejaculation (PE) in mainlandChina, US, Taiwan, Hong Kong and Macau respectively. The investigational new drug (IND) for Clinical Trial Approval (CTA) has been submitted to the Center of Drug Evaluation of the National Medical Products Administration by Wanbang Pharmaceutical Marketing and Distribution Co. Ltd. ("Wanbang Pharmaceutical"), a wholly controlled company of Shanghai Fosun Pharma, Regent Pacific's commercial strategic partner in China to seek marketing approval of Senstend™ in China. It is expected that the approval would be obtained by the end of First Quarter 2021. Upon receiving the approval, Regent Pacific will receivea total payment of USD 4 million from Wanbang Pharmaceutical as per the terms of the licence agreement. The payment will be divided into two terms, USD 800,000 will be received upon the approval from NMPA to submit IND application for human clinical trial of a licensed product at NMPA. The remaining US$3.20 million (HK$24.96 million) will be received upon the receipt of the approval from the NMPA to conduct a human clinical trial of a licensed product or written NMPA acceptance as sufficient of provided data without need for conducting a further clinical trial. In the United States, The Phase II validation study of Fortacin™ by the U.S. Food and Drug Administration ("US FDA") is expected to be completed by the end of 2020, followed by the submission to the FDA in the first half of 2021. The pivotal Phase III study is expected to commence in the latter half of 2021, with New Drug Application ("NDA") submission possible in late 2022, giving a Prescription Drug User Fee Act date at the end of 2023 and contribute to the acquisition of all necessary regulatory approvals needed to commercialise Fortacin™ in the United States. In Taiwan, the Taiwan FDA ("TFDA") has recently approved the Drug Master Files for lidocaine and prilocaine, the active pharmaceutical ingredients of Fortacin™; and also, the plant master file application for the manufacturer of Fortacin™. It is anticipated that the approval could be obtained from TFDA by early 2021 which will trigger a payment of USD 300,000 to the Group. In addition, Fortacin™ is expected to be launched in Hong Kong and Macau in 2021, a delay as a result of the COVID-19 pandemic which significantly affected the number of orders. Since Regent Pacific's European marketing and distribution partner for Fortacin™ is based in Italy, it has been affected by the COVID-19 pandemic. During Third Quarter 2020, the European markets continued to be affected by the pandemic due both to the restrictions imposed to limit contagion in all territories, as well as from a cautious management of stocks by wholesalers. It is expected that the COVID-19 pandemic will continue to affect sales inQ4 2020, but with the sales activities gradually resuming to normal in the latter half of 2021. Necessary measures have been adopted so that the production and distribution activities of the product would not be affected. Fortacin™ /Sendstend™ is the first solution to premature ejaculation (PE) that does not act on the central nervous system and offers bona fide therapeutic efficacy that has been validated through extensive clinical trials in Europe, with over 23,500 doses delivered to trial participants. The solution is a topical spray containing low doses of lidocaine and prilocaine that take effect almost immediately upon application, giving users more control without reducing pleasure. Fully approved by the European Medicines Agency (EMA), Fortacin™ is now available in France, Germany, Italy, Portugal, Spain and the UK.お知らせ • Sep 03Regent Pacific Group Limited (SEHK:575) signed legally binding share purchase agreement to acquire majority stake in Deep Longevity, Inc.Regent Pacific Group Limited (SEHK:575) signed legally binding share purchase agreement to acquire majority stake in Deep Longevity, Inc. on September 2, 2020. In a separate transaction, Regent Pacific Group Limited signed agreement to acquire minority stake in Deep Longevity, Inc. Under the terms of transactions for both sellers, Regent Pacific Group will issue approximately 422.69 million consideration shares. Following the transaction, Deep Longevity will be a wholly owned subsidiary of Regent Pacific Group Limited. The transaction is subject to customary closing conditions, including shareholder approval in respect of a specific mandate required to issue the consideration shares, inter-conditional upon other merger agreement, listing committee of the Hong Kong stock exchange granting the listing of, and permission to deal in, the consideration shares, and obtaining of all necessary approvals and documents required under the laws of the Cayman Islands for the effective transfer of the Sale Shares to the Company. The transaction is expected to close before December 31, 2020.お知らせ • Aug 16Regent Pacific Group Limited to Report Q2, 2020 Results on Aug 24, 2020Regent Pacific Group Limited announced that they will report Q2, 2020 results on Aug 24, 2020株主還元RPGDE PharmaceuticalsDE 市場7D-5.5%6.4%3.9%1Y-31.0%26.5%2.6%株主還元を見る業界別リターン: RPG過去 1 年間で26.5 % の収益を上げたGerman Pharmaceuticals業界を下回りました。リターン対市場: RPGは、過去 1 年間で2.6 % のリターンを上げたGerman市場を下回りました。価格変動Is RPG's price volatile compared to industry and market?RPG volatilityRPG Average Weekly Movement7.1%Pharmaceuticals Industry Average Movement6.4%Market Average Movement6.1%10% most volatile stocks in DE Market12.9%10% least volatile stocks in DE Market2.7%安定した株価: RPG 、 German市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: RPGの 週次ボラティリティ は、過去 1 年間で14%から7%に減少しました。会社概要設立従業員CEO（最高経営責任者ウェブサイト199116Jamie Alexander Gibsonwww.regentpac.comリージェント・パシフィック・グループ・リミテッドは投資持株会社で、欧州、米国、アジア太平洋地域のヘルスケア・ライフサイエンス分野に投資を行っている。同社はバイオファーマ部門と企業投資部門を通じて事業を展開している。泌尿器疾患の治療・管理用医薬品の研究・開発・製造・マーケティング・販売、分子・細胞・組織・臓器・システム・生理・心理レベルで老化速度を追跡する人工知能システムの開発などを手がけている。また、上場・非上場企業への投資も行っている。さらに、経営サービスも提供している。旧社名はエンデュランスRPリミテッドで、2023年7月にリージェント・パシフィック・グループ・リミテッドに社名変更した。リージェント・パシフィック・グループ・リミテッドは1991年に設立され、香港のセントラルに本社を置く。もっと見るRegent Pacific Group Limited 基礎のまとめRegent Pacific Group の収益と売上を時価総額と比較するとどうか。RPG 基礎統計学時価総額€21.12m収益（TTM）-€4.05m売上高(TTM)€311.82k67.7xP/Sレシオ-5.2xPER（株価収益率RPG は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計RPG 損益計算書（TTM）収益US$363.00k売上原価US$783.00k売上総利益-US$420.00kその他の費用US$4.29m収益-US$4.71m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）-0.016グロス・マージン-115.70%純利益率-1,297.52%有利子負債／自己資本比率-54.6%RPG の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/25 21:48終値2026/05/25 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Regent Pacific Group Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Keith RedpathCavendishSanjay JhaHybridan LLP
Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Adrian Alan Chan was the last director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • May 07Regent Pacific Group Limited, Annual General Meeting, May 29, 2026Regent Pacific Group Limited, Annual General Meeting, May 29, 2026, at 15:00 China Standard Time. Location: room 302, 3/f, first commercial building, 33-35 leighton road, causeway bay, Hong Kong
お知らせ • Mar 16Regent Pacific Group Limited to Report Fiscal Year 2025 Results on Mar 26, 2026Regent Pacific Group Limited announced that they will report fiscal year 2025 results at 12:30 PM, China Standard Time on Mar 26, 2026
お知らせ • Aug 15Regent Pacific Group Limited to Report First Half, 2025 Results on Aug 27, 2025Regent Pacific Group Limited announced that they will report first half, 2025 results on Aug 27, 2025
お知らせ • Jun 30Regent Pacific Group Limited Announces Change in Composition of the Nomination CommitteeRegent Pacific Group Limited announced that Mrs. Jayne Sutcliffe, a Non-Executive Director, and Mr. Ihsan Al Chalabi, an Independent Non-Executive Director, have been appointed as a member of the nomination committee of the Company (the "Nomination Committee") with effect from 30 June 2025. Following the above changes, the composition of the Nomination Committee comprises five members, namely James Mellon (Chairman of the Nomination Committee), Jayne Sutcliffe, Mark Searle, Adrian Chan and Ihsan Al Chalabi.
お知らせ • Apr 28Regent Pacific Group Limited, Annual General Meeting, Jun 19, 2025Regent Pacific Group Limited, Annual General Meeting, Jun 19, 2025, at 15:00 China Standard Time. Location: 14/f, fairmont house, 8 cotton tree drive, central, Hong Kong
Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Adrian Alan Chan was the last director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • May 07Regent Pacific Group Limited, Annual General Meeting, May 29, 2026Regent Pacific Group Limited, Annual General Meeting, May 29, 2026, at 15:00 China Standard Time. Location: room 302, 3/f, first commercial building, 33-35 leighton road, causeway bay, Hong Kong
お知らせ • Mar 16Regent Pacific Group Limited to Report Fiscal Year 2025 Results on Mar 26, 2026Regent Pacific Group Limited announced that they will report fiscal year 2025 results at 12:30 PM, China Standard Time on Mar 26, 2026
お知らせ • Aug 15Regent Pacific Group Limited to Report First Half, 2025 Results on Aug 27, 2025Regent Pacific Group Limited announced that they will report first half, 2025 results on Aug 27, 2025
お知らせ • Jun 30Regent Pacific Group Limited Announces Change in Composition of the Nomination CommitteeRegent Pacific Group Limited announced that Mrs. Jayne Sutcliffe, a Non-Executive Director, and Mr. Ihsan Al Chalabi, an Independent Non-Executive Director, have been appointed as a member of the nomination committee of the Company (the "Nomination Committee") with effect from 30 June 2025. Following the above changes, the composition of the Nomination Committee comprises five members, namely James Mellon (Chairman of the Nomination Committee), Jayne Sutcliffe, Mark Searle, Adrian Chan and Ihsan Al Chalabi.
お知らせ • Apr 28Regent Pacific Group Limited, Annual General Meeting, Jun 19, 2025Regent Pacific Group Limited, Annual General Meeting, Jun 19, 2025, at 15:00 China Standard Time. Location: 14/f, fairmont house, 8 cotton tree drive, central, Hong Kong
お知らせ • Mar 17Regent Pacific Group Limited to Report Fiscal Year 2024 Results on Mar 27, 2025Regent Pacific Group Limited announced that they will report fiscal year 2024 results on Mar 27, 2025
お知らせ • Dec 19Regent Pacific Group Limited Announces Submission of Senstend New Drug Application to the National Medical Products Administration in ChinaThe Board announced that commercial strategic partner Jiang Su Wan Bang Sheng Hua Yi Yao Ji Tuan You Xian Ze Ren Gong Si (Jiangsu Wanbang Biopharmaceutical Group Co. Ltd.) ("Wanbang Biopharmaceutical", a wholly-controlled company of Shanghai Fosun Pharmaceutical (Group) Co. Ltd. ("Fosun")) has submitted the New Drug Application ("NDA") registration dossier with the National Medical Products Administration ("NMPA") on 17 December 2024, with approval expected within 12 months from the submission date. Wanbang Biopharmaceutical is responsible, at its own expense, for obtaining the NDA from NMPA and maintaining any and all regulatory approvals required for the importation of Senstend in the People's Republic of China ("China" or "PRC"). In addition, and importantly, Wanbang Biopharmaceutical has signed an exclusive manufacturing and supply agreement with, inter alia, Genetic S.p. A. ("Genetic") and Jiang Su Wan Bang Yi Yao Ying Xiao You Xian Gong Si (Wanbang Pharmaceutical Marketing and Distribution Co. Ltd) ("Wanbang MKT", an affiliate of Wanbang Biopharmaceutical) on 26 August 2024, where Genetic will manufacture and supply Senstend to Wanbang Biopharmaceutical based on purchase orders received from Wanbang Biopharmaceutical. As previously mentioned, on the NDA being approved by NMPA, USD 5 million (or approximately HKD 39 million) and on first commercial launch USD 2 million (or approximately HKD 15.60 million) will be payable to the Group from Wanbang Biopharm pharmaceutical.
Reported Earnings • Sep 27First half 2024 earnings released: US$0.011 loss per share (vs US$0.055 loss in 1H 2023)First half 2024 results: US$0.011 loss per share (improved from US$0.055 loss in 1H 2023). Revenue: US$43.0k (down 85% from 1H 2023). Net loss: US$2.62m (loss narrowed 79% from 1H 2023). Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 51% per year, which means it is performing significantly worse than earnings.
お知らせ • Aug 16Regent Pacific Group Limited to Report First Half, 2024 Results on Aug 28, 2024Regent Pacific Group Limited announced that they will report first half, 2024 results on Aug 28, 2024
お知らせ • Apr 28Regent Pacific Group Limited, Annual General Meeting, May 30, 2024Regent Pacific Group Limited, Annual General Meeting, May 30, 2024, at 15:00 China Standard Time. Location: 14/F, Fairmont House, 8 Cotton Tree Drive, Central Hong Kong Agenda: To receive, consider and adopt the audited financial statements of the Company and the reports of the Directors and the independent auditor of the Company for the year ended 31 December 2023; to re-appoint RSM Hong Kong as the independent auditor of the Company and to authorise the Board to fix their remuneration; to re-elect the following Directors, each as a separate ordinary resolution, and to authorise the Board to fix the remuneration of the Directors for the year ending 31 December 2024; and to consider other matters.
Reported Earnings • Mar 29Full year 2023 earnings released: US$0.11 loss per share (vs US$0.30 loss in FY 2022)Full year 2023 results: US$0.11 loss per share (improved from US$0.30 loss in FY 2022). Net loss: US$25.0m (loss narrowed 31% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has fallen by 51% per year, which means it is performing significantly worse than earnings.
お知らせ • Mar 26Qujing Black Gold Energy Co., Ltd. entered into a sale and purchase agreement to acquire 25% stake in West China Coking & Gas Company Limited from Regent Pacific Group Limited (SEHK:575) for CNY 8 million.Qujing Black Gold Energy Co., Ltd. entered into a sale and purchase agreement to acquire 25% stake in West China Coking & Gas Company Limited from Regent Pacific Group Limited (SEHK:575) for CNY 8 million on March 24, 2024. The consideration consists of CNY 8 million in cash. As part of the consideration, CNY 8 million was paid towards common equity. . West China Coking & Gas Company Limited reported the unaudited net loss of CNY 8.9 million as at 31 December 2023. The completion of the transaction is conditional upon all necessary corporate, governmental or regulatory approvals of the Disposal (the “Conditions”) including but not limited to unanimous approval from the shareholders of the Target Company and any relevant PRC governmental or regulatory bodies.
お知らせ • Mar 16Regent Pacific Group Limited to Report Fiscal Year 2023 Results on Mar 27, 2024Regent Pacific Group Limited announced that they will report fiscal year 2023 results on Mar 27, 2024
お知らせ • Aug 18Regent Pacific Group Limited to Report First Half, 2023 Results on Aug 29, 2023Regent Pacific Group Limited announced that they will report first half, 2023 results on Aug 29, 2023
お知らせ • Jul 23Regent Pacific Group Limited Provides Consolidated Earnings Guidance for the Period Ended 30 June 2023Regent Pacific Group Limited provided consolidated earnings guidance for the period ended 30 June 2023. The group expects to record a loss attributable to the equity holders of the company for the period ended 30 June 2023 (the "Reporting Period") of between approximately USD 12 million (or approximately HKD 93.60 million) to approximately USD 15 million (or approximately HKD 117 million), which represents a substantial decrease in the loss as compared to a loss attributable to the equity holders of the Company of approximately USD 20.06 million (or approximately HKD 156.47 million) for the period ended 30 June 2022 (the "Corresponding Period").
Board Change • Jul 12Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 5 highly experienced directors. Independent Non-Executive Director Julie Oates was the last director to join the board, commencing their role in 2004. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Reported Earnings • Mar 30Full year 2022 earnings released: US$0.015 loss per share (vs US$0.005 loss in FY 2021)Full year 2022 results: US$0.015 loss per share (further deteriorated from US$0.005 loss in FY 2021). Net loss: US$36.4m (loss widened 189% from FY 2021). Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has only increased by 39% per year, which means it is significantly lagging earnings growth.
お知らせ • Feb 18Endurance RP Limited Provides Earnings Guidance for the Year Ended 31 December 2022Endurance RP Limited provided earnings guidance for the year ended 31 December 2022. For the year, the Group expects to record a loss attributable to the equity holders of the Company of between approximately USD 33 million (or approximately HKD 257.40 million) to approximately USD 36 million (or approximately HKD 280.80 million), which represents a substantial increase in the loss as compared to the loss attributable to the equity holders of the Company of approximately USD12.60 million (or approximately HKD 98.28 million) for the year ended 31 December 2021 (the Corresponding Period).
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 5 highly experienced directors. Independent Non-Executive Director Charles David Comba was the last director to join the board, commencing their role in 2005. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • Aug 19Endurance RP Limited to Report First Half, 2022 Results on Aug 30, 2022Endurance RP Limited announced that they will report first half, 2022 results on Aug 30, 2022
お知らせ • Jul 23Endurance RP Limited Provides Unaudited Consolidated Earnings Guidance for the Period Ended 30 June 2022Endurance RP Limited provided unaudited consolidated earnings guidance for the period ended 30 June 2022. For the period, the Group expects to record a loss attributable to the equity holders of the Company between approximately USD 20 million (or approximately HKD 156 million) to approximately USD 23 million (or approximately HKD 179.40 million), which represents a loss as compared to a profit attributable to the equity holders of the Company of approximately USD 2.66 million (or approximately HKD 20.75 million) for the period ended 30 June 2021.
お知らせ • Jul 06Endurance Rp Limited Announces Operational Update on the PE Prevention Drug Fortacin/ SenstendEndurance RP Limited provided updates on the PE prevention drug - Fortacin /Senstend (the marketing name of Fortacin in China). Regarding the clinical study for seeking approval of an import licence for Senstend™ from the National Medical Products Administration of The People's Republic of China ("China"), among the three drug trials that Wanbang Biopharmaceutical Co. Ltd. (Wanbang Biopharmaceutical), the Company's commercial strategic partner for China and a wholly controlled company of Shanghai Fosun Pharmaceutical (Group) Co. Ltd. registered in December 2021 with the Centre of Drug Evaluation, the two Phase 1 studies have been successfully completed and the remaining Phase 3 study remains ongoing. Despite certain COVID-19 lockdowns and restrictions being experienced in China, the Phase 3 study has commenced with 177 patients having signed informed consent forms to enter the study (approximately 62% complete) and 88 subjects having been randomised into the study (approximately 31% complete) as of 1 July 2022. Wanbang Biopharmaceutical has advised the Company that even with the aforementioned COVID-19 lockdowns and restrictions, enrolment and randomisation is estimated to complete in November 2022. The preparatory phase for preparing the New Drug Application ("NDA") to NMPA have been commenced with the aim of submitting the NDA by the end of Second Quarter 2023. All costs of the clinical trials, including all other associated regulatory and submission costs are being met by Wanbang Biopharmaceutical. If the clinical study meets its endpoints and the NMPA grants an import licence for Senstend, USD 5 million (or approximately HKD 39 million before deduction of PRC withholding tax) will be payable to the Group from Wanbang Biopharmaceutical. In addition, upon first commercial sale of Senstend in China, USD 2 million (or approximately HKD 15.60 million before deduction of PRC withholding tax) shall be payable to the Group from Wanbang Biopharmaceutical.
Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 5 highly experienced directors. Independent Non-Executive Director Charles David Comba was the last director to join the board, commencing their role in 2005. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Reported Earnings • Mar 31Full year 2021 earnings releasedFull year 2021 results: Revenue: US$18.2m (up US$17.0m from FY 2020). Net loss: US$12.6m (loss narrowed 48% from FY 2020).
お知らせ • Feb 16Endurance RP Limited Provides Consolidated Earnings Guidance for the Period Ended December 31, 2021Endurance RP Limited provided consolidated earnings guidance for the period ended December 31, 2021. For the year, the Group expects to record a loss attributable to the equity holders of the Company for the year ended31 December 2021 of between approximately USD 11.50 million (or approximately HKD 89.70 million) to approximately USD 14.00 million (or approximately HKD 109.20 million), which represents a substantial decrease in the loss as compared to a loss attributable to the equity holders of the Company of approximately USD 24.40 million (or approximately HKD 190.32 million) for the year ended 31 December 2020.
Reported Earnings • Sep 28First half 2021 earnings released: EPS US$0.001 (vs US$0.015 loss in 1H 2020)First half 2021 results: Net income: US$2.66m (up US$29.8m from 1H 2020). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.
お知らせ • Jul 16Endurance Rp Limited Announces Completion of Prespecified Data Analysis from the 16 Centre United States StudyEndurance RP Limited announced successful completion of prespecified data analysis from the 16 centre United States study undertaken to validate the Food and Drug Administration mandated patient reported outcome for premature ejaculation. The PRO, the Premature Ejaculation Bothersome Evaluation Questionnaire was developed compliant to FDA guidelines as the key final step for assessment of efficacy ahead of the Phase III randomised clinical trial already planned for the US. In this study, PSD502, marketed as FortacinTM in the European Union and the United Kingdom, produced substantial changes in intravaginal latency time ("IELT") and reduced the level of distress experienced by patients, as reflected in the PEBEQ. These results are entirely consistent with the previous extensive Phase III RCTs that were successfully completed prior to approval by the European Medicines Agency. The changes were clinically and statistically significant both from baseline and from placebo, resulting in an eight-to-nine-fold increase from pre-treatment IELT values. Also consistent with previous RCTs, compliance with therapy and with study requirements was high (over 92% completed in this study), and side effects were minimal. Clinically and statistically significant differences between Fortacin and placebo were observed in the FDA-favoured domain ("Item 3") of the PEBEQ (p< 0.0008). At the request of the FDA, Item 3 was designed to determine the degree of "bother" that the patients were experiencing due to the condition. For PRO validation, excellent correlations were also observed between changes in Item 3 of the PEBEQ and the domains of sexual satisfaction, control and distress captured using the Index of Premature Ejaculation ("IPE"), one of two PROs used in previous studies. The terms such as "bother" are important because they are used in the final approved prescribing information ("PI"). Overall, the study confirms the safety and efficacy of Fortacin. The new data will be used to refine the final Phase III RCT protocol, which is already prepared, and suitable clinical sites screen for expedient and good clinical practice enrolment. Formal registration of the Phase II validation study of FortacinTM is a critical and positive step towards making the new drug application ("NDA") submission and ultimately achieving all necessary FDA and other regulatory approvals needed to commercialise of FortacinTM in the US, its most significant potential market.
Executive Departure • Jun 08Company Secretary Yuk Fung has left the companyOn the 1st of June, Yuk Fung's tenure as Company Secretary ended. We don't have any record of a personal shareholding under Yuk's name. Yuk is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 18.42 years.
Reported Earnings • Apr 02Full year 2020 earnings released: US$0.013 loss per share (vs US$0.036 loss in FY 2019)Full year 2020 results: Net loss: US$24.4m (loss narrowed 63% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings.
お知らせ • Mar 19Regent Pacific Group Limited to Report Fiscal Year 2020 Results on Mar 30, 2021Regent Pacific Group Limited announced that they will report fiscal year 2020 results on Mar 30, 2021
お知らせ • Feb 10Wanbang Biopharmaceutical Group Co., Ltd. Obtains Clinical Trial Approval for Senstend from the Center of Drug Evaluation on February 5, 2021Regent Pacific Group Limited announced that Wanbang Biopharmaceutical Group Co. Ltd., the Company's commercial strategic partner for China, obtained Clinical Trial Approval for Senstend™ from the Center of Drug Evaluation on February 5, 2021, which has triggered a payment of $3.20 million before deduction of PRC withholding tax from Wanbang Biopharmaceutical. The randomised clinical trial is expected to commence in April/May 2021, with an estimated completion time of 12 months. Wanbang Biopharmaceutical has appointed a leading contract research organisation to undertake the randomised clinical trial. If the clinical study meets its endpoints and NMPA has granted an import licence for Senstend™, Regent Pacific will receive a payment of $5 million from Wanbang Biopharmaceutical. In addition, upon the first commercial sale of Senstend in China, the Group will receive another payment of $2 million from Wanbang Biopharmaceutical. In addition, the Group will generate low to mid-teens royalties of Wangbang Biopharmaceutical's net sales of Senstend in China.
お知らせ • Jan 20Regent Pacific Group Limited Announces Operation Update on FortacinThe Directors of Regent Pacific Group Limited reported that Orient EuroPharma Co., Ltd. ("OEP"), the Group's commercial strategic partner for Taiwan, Hong Kong Special Administrative Region Macau Special Administrative Region ("Macau") and other select countries in Asia, has launched FortacinTM, the Group's prescription treatment for premature ejaculation, for sale in Hong Kong from this month. OEP has also informed the Group that it expects to launch FortacinTM in Macau in March 2021 and in Taiwan (its home market) in April 2021. The Group will generate a low teens royalty of OEP's net sales of FortacinTM in these markets. This marks a pivotal moment for the Group in realising its strategic goal of offering FortacinTM, through OEP, in its home market of Hong Kong. The Group also informed the shareholders that Wanbang Biopharmaceutical Group Co., Ltd., the Company's commercial strategic partner for China, has appointed a leading contract research organisation to undertake the randomised clinical trial in China. The randomised clinical trial is due to commence in April /May 2021, subject to the approval from National Medical Products Administration. The Group is in early discussions with a potential partner for "out licensing" the rights to FortacinTM for Japan. While these developments are indeed exciting, it is not possible to determine with accuracy the timing of completion of such discussions, and no assurance can be given that negotiations will lead to a binding Licensing agreement(s).
お知らせ • Jan 05Regent Pacific Group Limited Announces Key Progresses on FORTACIN(TM)/SENSTEND(TM) - Solution to Premature EjaculationRegent Pacific Group Limited announced several key updates of Fortacin™/Senstend™, the first prescription solution to premature ejaculation (PE) that does not act on the central nervous system, in China and the United States respectively. Regent Pacific received USD 0.72 million (approximately HKD 5.62 million) from its commercial strategic partner in China -Wanbang Pharmaceutical Marketing and Distribution Co. Ltd. ("Wanbang Pharmaceutical"), a wholly controlled company of Shanghai Fosun Pharma to seek marketing approval of Senstend™ (the marketing name of Fortacin™ in China) in China on 29 December 2020. The Clinical Trial Approval ("CTA") of Senstend™ will be reviewed by the National Medical Products Administration ("NMPA") and is expected to be obtained from the Center of Drug Evaluation by the end of first quarter of 2021. Upon the successful approval from NMPA to commence the clinical trial, Regent Pacific will receive a payment of USD 3.20 million (approximately HKD 24.96 million) from Wanbang Pharmaceutical. Regent Pacific will receive USD 5 million (approximately HKD 39 million) from Wanbang Pharmaceutical if the clinical study tentatively to be started in April/May 2021 meets its endpoints of determining the effects of Senstend™ on the Index of Premature Ejaculation (IPE) and the Intra-vaginal Ejaculation Latency Time (IELT) and to evaluate the safety and tolerability of Senstend™ in Premature Ejaculation subjects and their sexual partners, together with an import licence for Senstend™ granted by NMPA. Regent Pacific will also receive USD 2 million (approximately HKD 15.6 million) upon the first commercial sale of Senstend™ in China from Wanbang Pharmaceutical with tiered percentage royalties on net sales, ranging from low to the high teens from first commercial sale.
お知らせ • Dec 04Regent Pacific Group Limited Provides Operations Update on FortacinThe directors of Regent Pacific Group Limited provided update in respect of its operations in relation SenstendTM/FortacinTM. Further to the last operations update issued by the Company on 17 November 2020, the Directors are pleased to inform shareholders that Wanbang Pharmaceutical Marketing and Distribution Co. Ltd. ("Wanbang Pharmaceutical"), the Company's commercial strategic partner for China, has received approval from the National Medical Products Administration ("NMPA") to submit the investigational new drug application for human clinical trial of a Licensed Product at NMPA, which is an important milestone in achieving approval to market SenstendTM in China. Plethora has accordingly issued to Wanbang Pharmaceutical an invoice for USD 800,000 (or approximately HKD 6.24 million), which is payable within 30 business days. NMPA will now formally review for Clinical Trial Approval ("CTA") and the Company has been advised by Wanbang Pharmaceutical that the CTA will be obtained from the Center of Drug Evaluation within 60 working days (approximately 3 months) from the date of submission, i.e. by end of first quarter 2021. Upon the successful approval from NMPA to commence the clinical trial a payment of USD 3.20 million (or approximately HKD 24.96 million) will be due. The Group will continue to work closely and diligently with its current and prospective commercial partners and will keep shareholders and potential investors informed of any new developments as and when they occur.
お知らせ • Nov 18Regent Pacific Announces Important Commercialisation Progress on Fortacin/ SenstendRegent Pacific Group Limited announced several important commercialisation progress on SENSTEND™ (the marketing name of FORTACIN™ in mainlandChina), the first prescription treatment for treating premature ejaculation (PE) in mainlandChina, US, Taiwan, Hong Kong and Macau respectively. The investigational new drug (IND) for Clinical Trial Approval (CTA) has been submitted to the Center of Drug Evaluation of the National Medical Products Administration by Wanbang Pharmaceutical Marketing and Distribution Co. Ltd. ("Wanbang Pharmaceutical"), a wholly controlled company of Shanghai Fosun Pharma, Regent Pacific's commercial strategic partner in China to seek marketing approval of Senstend™ in China. It is expected that the approval would be obtained by the end of First Quarter 2021. Upon receiving the approval, Regent Pacific will receivea total payment of USD 4 million from Wanbang Pharmaceutical as per the terms of the licence agreement. The payment will be divided into two terms, USD 800,000 will be received upon the approval from NMPA to submit IND application for human clinical trial of a licensed product at NMPA. The remaining US$3.20 million (HK$24.96 million) will be received upon the receipt of the approval from the NMPA to conduct a human clinical trial of a licensed product or written NMPA acceptance as sufficient of provided data without need for conducting a further clinical trial. In the United States, The Phase II validation study of Fortacin™ by the U.S. Food and Drug Administration ("US FDA") is expected to be completed by the end of 2020, followed by the submission to the FDA in the first half of 2021. The pivotal Phase III study is expected to commence in the latter half of 2021, with New Drug Application ("NDA") submission possible in late 2022, giving a Prescription Drug User Fee Act date at the end of 2023 and contribute to the acquisition of all necessary regulatory approvals needed to commercialise Fortacin™ in the United States. In Taiwan, the Taiwan FDA ("TFDA") has recently approved the Drug Master Files for lidocaine and prilocaine, the active pharmaceutical ingredients of Fortacin™; and also, the plant master file application for the manufacturer of Fortacin™. It is anticipated that the approval could be obtained from TFDA by early 2021 which will trigger a payment of USD 300,000 to the Group. In addition, Fortacin™ is expected to be launched in Hong Kong and Macau in 2021, a delay as a result of the COVID-19 pandemic which significantly affected the number of orders. Since Regent Pacific's European marketing and distribution partner for Fortacin™ is based in Italy, it has been affected by the COVID-19 pandemic. During Third Quarter 2020, the European markets continued to be affected by the pandemic due both to the restrictions imposed to limit contagion in all territories, as well as from a cautious management of stocks by wholesalers. It is expected that the COVID-19 pandemic will continue to affect sales inQ4 2020, but with the sales activities gradually resuming to normal in the latter half of 2021. Necessary measures have been adopted so that the production and distribution activities of the product would not be affected. Fortacin™ /Sendstend™ is the first solution to premature ejaculation (PE) that does not act on the central nervous system and offers bona fide therapeutic efficacy that has been validated through extensive clinical trials in Europe, with over 23,500 doses delivered to trial participants. The solution is a topical spray containing low doses of lidocaine and prilocaine that take effect almost immediately upon application, giving users more control without reducing pleasure. Fully approved by the European Medicines Agency (EMA), Fortacin™ is now available in France, Germany, Italy, Portugal, Spain and the UK.
お知らせ • Sep 03Regent Pacific Group Limited (SEHK:575) signed legally binding share purchase agreement to acquire majority stake in Deep Longevity, Inc.Regent Pacific Group Limited (SEHK:575) signed legally binding share purchase agreement to acquire majority stake in Deep Longevity, Inc. on September 2, 2020. In a separate transaction, Regent Pacific Group Limited signed agreement to acquire minority stake in Deep Longevity, Inc. Under the terms of transactions for both sellers, Regent Pacific Group will issue approximately 422.69 million consideration shares. Following the transaction, Deep Longevity will be a wholly owned subsidiary of Regent Pacific Group Limited. The transaction is subject to customary closing conditions, including shareholder approval in respect of a specific mandate required to issue the consideration shares, inter-conditional upon other merger agreement, listing committee of the Hong Kong stock exchange granting the listing of, and permission to deal in, the consideration shares, and obtaining of all necessary approvals and documents required under the laws of the Cayman Islands for the effective transfer of the Sale Shares to the Company. The transaction is expected to close before December 31, 2020.
お知らせ • Aug 16Regent Pacific Group Limited to Report Q2, 2020 Results on Aug 24, 2020Regent Pacific Group Limited announced that they will report Q2, 2020 results on Aug 24, 2020
